Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mexidol in chronic cerebral ischemia
NCT06834490Phase 3Completed
- Sponsor
- Pharmasoft
- Start
- Nov 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in chronic cerebral ischemia comparing Main (Mexidol) with Control (Placebo) (2 arms). Primary endpoint: Montreal Cognitive Assessment at 75 days. Started Nov 2019; status: completed.
02
Drugs
emoxypine
03
Conditions
chronic cerebral ischemia
Beyond the preview
Go deeper on NCT06834490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06834490.